

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Segura et al

Confirmation No: 9630

Serial No.: 10/560,260

Group Art Unit: TBA

Filed: December 9, 2005

Examiner: TBA

For: Antimicrobial Peptides

REQUEST FOR WITHDRAWAL OF ABANDONMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

A Notice of Abandonment dated January 18, 2008 was recently received on the above-identified application. The reason stated for abandonment was the alleged failure of Applicants to respond to the Notification of Missing Requirements (Form PCT/DO/EO/905), mailed March 9, 2006. Applicants request that the Notice of Abandonment be withdrawn since a response to the Notification of Missing Requirements was in fact filed in a timely manner on May 3, 2006, and this response was received by the PTO. To support Applicants' position, Applicants enclose a copy of the response, a certificate of mailing and the date-stamped postcard indicating receipt of all these documents in the PTO mailroom.

Since the postcard plainly shows that the error lies with the PTO, Applicants respectfully request the withdrawal of the abandonment by the PTO without requiring Applicants to file a Petition to Revive.

Respectfully submitted,

Date: January 24, 2008

/Elias Lambiris, Reg. # 33728/  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

Attorney Docket No.: 10328.204-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Segura et al

Confirmation No: 9630

Serial No.: 10/560,260

Group Art Unit: TBA

Filed: December 9, 2005

Examiner: TBA

For: Antimicrobial Peptides

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Response to Notice to File Missing Parts and the Notice to Comply with Sequence Rules
2. Disk Containing Sequence Listing
3. Copy of Notice to Comply with Sequence Rules

is being deposited with the United States Postal Service as first class mail in an envelope addressed to the address indicated above on May 3, 2006.

Julie Tabarovsky

(name of person mailing paper)



(signature of person mailing paper)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Segura et al

Confirmation No: 9630

Serial No.: 10/560,260

Group Art Unit: TBA

Filed: December 9, 2005

Examiner: TBA

For: Antimicrobial Peptides

**RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE REQUIREMENTS**

Mail Stop Sequence  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


This paper is in response to the Notice to Comply with Sequence Requirements dated March 9, 2006. The Notice stated that the computer readable form that was filed with the application or filed on December 9, 2005 was not the same as the paper copy of the Sequence Listing.

Applicants therefore enclose another computer readable form of the Sequence Listing. The content of the paper copy that was filed with the application and of the enclosed computer readable form is the same. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: May 3, 2006



Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/560,260	Dorotea Raventos Segura	10328.204-US
INTERNATIONAL APPLICATION NO.		
PCT/DK04/00400		
I.A. FILING DATE	PRIORITY DATE	
06/10/2004	06/11/2003	

25908  
NOVOZYMES NORTH AMERICA, INC.  
500 FIFTH AVENUE  
SUITE 1600  
NEW YORK, NY 10110

CONFIRMATION NO. 9630

371 FORMALITIES LETTER

\*OC000000018228731\*

Date Mailed: 03/09/2006

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

PAULETTE R KIDWELL

---

Telephone: (703) 308-9140 EXT 216

---

## PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/560,260	PCT/DK04/00400	10328.204-US

FORM PCT/DO/EO/922 (371 Formalities Notice)

Attorney Docket No. 10328.204-US  
Patent Application entitled: "Antimicrobial Peptides"  
Applicants: Segura et al  
USSN: 10/560,260

The USPTO hereby acknowledges receipt of the following:

1. Certificate of Mailing
2. Response to Notice to Comply with Sequence Rules
3. Copy of Notice to Comply With Requirements
4. Computer Readable Form of Sequence Listing

May 3, 2006

VIA First Class Mail

**AP3 Rec'd PCT/PTO 08 MAY 2006**

---